<DOC>
	<DOCNO>NCT00006053</DOCNO>
	<brief_summary>RATIONALE : STI571 may interfere growth cancer cell may effective treatment chronic myelogenous leukemia . PURPOSE : Phase II trial study effectiveness STI571 treat patient chronic myeloid leukemia respond interferon alfa .</brief_summary>
	<brief_title>STI571 Treating Patients With Chronic Myelogenous Leukemia That Has Not Responded Interferon Alfa</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate safety profile STI571 patient Philadelphia chromosome positive ( chromosome negative Bcr/Abl positive ) chronic phase chronic myelogenous leukemia refractory intolerant interferon alfa . II . Provide expand access treatment patient . III . Confirm rate complete major cytogenetic response patient treated regimen , demonstrate decrease percentage Philadelphia chromosome positive cell bone marrow . IV . Evaluate improvement symptomatic parameter patient treat regimen . OUTLINE : This expand access , multicenter study . Patients receive oral STI571 daily . Treatment continue 12 month absence disease progression unacceptable toxicity . Patients respond 12 month may continue therapy . PROJECTED ACCRUAL : Not determine</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis chronic phase chronic myelogenous leukemia ( CML ) Philadelphia ( Ph ) chromosome positive OR Bcr/Abl positive Refractory intolerant interferon alfa therapy Failure achieve complete response least 1 month least 6 month interferon alfa therapy OR At least 65 % Ph chromosome positivity bone marrow least 1 year interferon alfa therapy OR At least 30 % increase Ph chromosome positive bone marrow cell sample take least 1 month apart increase least 65 % receive interferon alfa therapy OR At least 100 % increase WBC count least 20,000/mm3 sample take least 2 week apart receive interferon alfa therapy OR At least grade 3 nonhematologic toxicity persist 2 week receive interferon alfa therapy ( must 3 month time diagnosis ) No great 15 % blast basophils peripheral blood bone marrow Less 30 % blast plus promyelocytes peripheral blood bone marrow PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 03 Life expectancy : Not specify Hematopoietic : Platelet count least 100,000/mm3 Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) SGOT SGPT great 2 time ULN Renal : Creatinine great 2 time ULN Cardiovascular : No New York Heart Association class III IV heart disease Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception least 2 week study woman least 3 month study men No history noncompliance prior medical regimen PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics At least 14 day since prior interferon alfa No concurrent biologic therapy Chemotherapy : At least 6 week since prior busulfan At least 14 day since prior cytarabine At least 7 day since prior hydroxyurea No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : At least 28 day since prior investigational agent No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic myelogenous leukemia , BCR-ABL1 positive</keyword>
	<keyword>Philadelphia chromosome negative chronic myelogenous leukemia</keyword>
</DOC>